TFPI, anti-TFPI, and Hemophilia

Jen Schroeder, MD, PhD

In this interview with Rare Disease Report during the 57th ASH Annual Meeting, Jen Schroeder, MD, PhD, of Bayer talks about the preclinical studies presented at the ASH meeting that has compelled the company to begin a phase 1 study with anti-tissue factor pathway inhibitor (anti-TFPI) antibody BAY-1093884 for the treatment of hemophilia A.


Printer Printing...